One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH) are the most common causes of chronic liver disease in industrialized countries. NAFLD has ...
Hepatic Disease: A Camu-Camu Fruit Extract to Reduce Liver Fat Aug. 21, 2024 — A research team has shown the benefits of camu-camu on non-alcoholic fatty liver disease. This exotic fruit reduces ...